When a general reader thinks about a biotech company's patents, the picture is usually a single famous molecule — an antibody, a drug. But the issued record of a large biologics company tells a wider story, because making and delivering a protein drug is itself an engineering problem, and the steps in that process are patentable. Regeneron's grant docket is a clean example. The molecules are there, but so is a layer of issued coverage on the manufacturing line and the delivery hardware around them. The week of 19 May 2026 added a new tile to the first part of that map.

On 19 May 2026, the U.S. patent office granted US12630890B2, "Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments." The headline claim is not a static molecule but a process: the issued claim text describes "a method for selecting a plurality of antibodies or antigen-binding fragments thereof for use in mitigating a frequency of escape mutants of a SARS"-type virus. That is a workflow claim — a way of choosing a combination of antibodies so the virus has fewer routes to evade them — and it reflects the practical lesson of the pandemic, when monoclonal antibodies repeatedly lost potency as the virus mutated. The abstract states the scope plainly:

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).— Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments, US12630890B2

The CPC classifications on the grant cluster in C07K 16/10 (antibodies against viral antigens) alongside C12Q 1/701 and G01N 33/56983 (viral nucleic-acid and detection methods), which is the signature of a record that mixes the molecule with the assay-and-selection method around it. For a business reader, the point is that the enforceable coverage here is partly about how you pick and validate the antibodies, not only the antibodies themselves — a distinction that matters because process and selection claims can constrain competitors even where the underlying targets are widely studied.

The footprint is built around the factory floor

What turns this into a coverage map is the surrounding estate, and Regeneron's recent grants lean heavily toward the operational side of biologics. On the manufacturing line, US12649764B2 covers a method for viral inactivation that modulates pH in a protein mixture — a routine but critical purification step where calculated acid additions hit a target pH to inactivate any virus carried through a chromatography column. Adjacent to it, US10520511B2 covers capillary-electrophoresis systems for determining the purity of multimeric proteins, explicitly aimed at the problem that "heterodimeric bispecific antibodies are often produced along with homodimer species, which can confound quantification" — in other words, an issued claim on the analytics that tell a manufacturer whether the right molecule actually came out of the process. Upstream of both, US10457959B2 covers a mammalian expression system using a GPT-based selection marker to raise recombinant-protein yield — coverage on the cell-line engineering that determines how much drug a batch produces.

The other half of the operational map is delivery. US12653952B2 covers a "dose delivery device fixture for testing system" — a syringe-holding fixture used to test prefilled syringes, which is coverage on the quality-control hardware behind a drug-device combination rather than on any drug. US12649031B2 covers methods for delivering agents with prefilled syringes "to minimize intraocular inflammation" in eye treatment — a device-and-method claim tied to how an ophthalmic biologic is administered. And US12642871B2 covers lyophilized formulations of adeno-associated-virus drug products, the freeze-dried stabilization chemistry that lets a gene-therapy product survive storage. Selection method, inactivation step, purity assay, expression system, dose-testing fixture, prefilled-syringe delivery, lyophilized formulation: the issued tiles trace the path of a biologic from cell line to vial to patient.

What the operational coverage buys

The business read on a coverage map like this is about where the freedom-to-operate pressure sits. A granted claim is the enforceable part of an estate, and Regeneron's recent grants concentrate on the steps that any biologics maker has to perform — purify the protein, inactivate viral contaminants, prove the molecule's purity, express it at scale, stabilize it, and deliver it. Coverage distributed across those steps is a different kind of position from a single molecule patent: it can put a competitor's process within reach of an issued claim even when the competitor's molecule is entirely its own. That is the practical meaning of an estate that reaches the factory floor and the syringe, and it shows up commercially as licensing discussions, design-arounds, and the engineering choices rivals make to stay clear of issued process claims.

The usual caveats apply to any coverage read. Issued claims describe what was granted, not how broadly a court would construe a process step or whether a given claim survives a validity challenge; manufacturing and analytical methods in particular often have crowded prior art. The older grants cited here reflect filings made years ago and run on their own term clocks, while the newest device and selection grants — including the 19 May 2026 antibody-selection patent and the June 2026 dose-fixture grant — show the estate still converting filings into issued coverage on the operational layer. But the pattern across Regeneron's record is consistent: alongside the molecules sit issued claims on the machinery that makes and delivers them. The 19 May 2026 grant adds a selection-method tile to that map, on the part of the workflow that decides which antibodies go forward in the first place.